Redesigning New Policy Options for Thalassemia Prevention in Sri Lanka
Thalassemia Reports · 2022
DOI: 10.3390/thalassrep12040018 ↗Kurz gefasst
Fachartikel in der Zeitschrift Thalassemia Reports, 2022. Verfasst von Nadeeja Amarasinghe und 7 weiteren Autor:innen. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Sri Lanka, a country with 22 million people, has nearly 2000 thalassemia patients with severe thalassemia, two-thirds of whom have beta thalassemia major (TM). The current prevention program based on promoting “safe marriages”, which has been in existence for over 15 years, has failed to reduce thalassemia major births. We set about to examine the cost-effectiveness of novel policy options for thalassemia prevention in Sri Lanka.
Methods
The current cost for treatment of a thalassemia major patient (USD 2602/yr) was compared against the cost per reduction of single birth with three novel strategies, namely intensifying the screening in the current five districts combined with an education program (policy option 1), a nationwide screening program (policy option 2), and antenatal screening combined with the termination of pregnancy (policy option 3). The incremental cost-effectiveness ratio (ICER) of the different strategies was calculated.
Results
The status quo was considered to reduce one TM birth whilst the new policy options were able to reduce births by 14, 35, and 48, respectively. The costs incurred for the program for a year for status quo and the three novel programs were USD 104,788, 173,884, 781,372, and 904,186 respectively. Cost per prevention of a thalassemia major birth was USD 87,324, 12,420, 22,324, and 20,084, respectively. The lifetime cost per treatment of a thalassemia major patient was USD 34,653.
Conclusions
Given the current legal restriction on termination of pregnancy for fetal indications, policy option 2, an island-wide screening with mass education, is the most cost-effective and will be expected to deliver a substantial reduction in new births.
Zitieren
APA
Amarasinghe, N., Amarasena, A., Thabrew, A., Werawatte, P., Premawardhena, A., Malik, F., Abusayeed, M., & Wickramasinghe, C. (2022). Redesigning New Policy Options for Thalassemia Prevention in Sri Lanka. Thalassemia Reports. https://doi.org/10.3390/thalassrep12040018
Vancouver
Amarasinghe N, Amarasena A, Thabrew A, Werawatte P, Premawardhena A, Malik F, et al. Redesigning New Policy Options for Thalassemia Prevention in Sri Lanka. Thalassemia Reports. 2022. doi:10.3390/thalassrep12040018
BibTeX
@article{Amarasinghe2022,
author = {Amarasinghe, Nadeeja and Amarasena, Amila and Thabrew, Anoj and Werawatte, Prabhath and Premawardhena, Anuja and Malik, Farnaz and Abusayeed, Mohamed and Wickramasinghe, Champika},
title = {Redesigning New Policy Options for Thalassemia Prevention in Sri Lanka},
journal = {Thalassemia Reports},
year = {2022},
doi = {10.3390/thalassrep12040018}
}
EUVIMED